CBIZ Agrees to $5B All-Cash Sale to Grant Thornton, Rescuing Shares from Post-Marcum Slide with 86% Premium

What happened

CBIZ, after a punishing post-Marcum integration that drove its stock down 66% from early 2025 highs, has entered a definitive agreement to be acquired by Grant Thornton Advisors for $55 per share in cash, a $5 billion enterprise value transaction backed by New Mountain Capital. The offer hands shareholders an immediate liquidity event at a price well above the DeepValue report’s bearish base case of $32 and even the bull scenario of $48, effectively neutralizing the overhanging risks of prolonged working-capital drag, independence-driven revenue leakage, and tight debt covenants. As part of the deal, CBIZ’s Benefits and Insurance Services segment will be spun off as an independent entity with New Mountain’s backing, potentially unlocking incremental value that the market had discounted amid the broader integration challenges. By merging with Grant Thornton, the combined entity aims to leverage enhanced AI capabilities and multinational reach, though the acquirer will now shoulder the very integration and regulatory complexities that weighed on CBIZ’s standalone valuation. For CBIZ shareholders, the buyout provides a definitive exit at a substantial premium, shifting the investment narrative from a drawn-out “prove it” phase to a clean cash collection, with the main remaining uncertainty being deal closure.

Implication

Patient shareholders receive a definitive exit above intrinsic value estimates, rewarding them for enduring the severe drawdown. The spin-off of Benefits & Insurance may offer additional equity upside if distributed, though most retail holders will simply tender for cash. The takeover caps further upside at the deal price, preventing participation in any long-term industry consolidation benefits, but given the execution risks, the premium is generous. For new investors, the remaining upside is limited to a narrow merger-arbitrage spread, making it unattractive unless a higher bid emerges. The primary risk is regulatory or shareholder rejection, but at this premium and with New Mountain’s support, closure probability appears high.

Thesis delta

The investment thesis shifts from a wait-and-see approach on integration execution to a straightforward merger-arbitrage event. The $55 cash offer obviates the need to assess working-capital normalization, margin recovery, or independence conflicts, instead delivering a near-term certain cash return. Investors should tender shares and evaluate any stub equity in the Benefits & Insurance spin-off if offered.